Aktis Oncology (NASDAQ:AKTS) Stock Price Up 6.6% – Should You Buy?

Shares of Aktis Oncology (NASDAQ:AKTS) rose 6.6% during mid-day trading on Tuesday . The stock traded as high as $22.12 and last traded at $22.0490. Approximately 46,609 shares traded hands during trading, a decline of 84% from the average daily volume of 297,901 shares. The stock had previously closed at $20.69.

Analysts Set New Price Targets

AKTS has been the subject of several research reports. HC Wainwright increased their price objective on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. William Blair initiated coverage on shares of Aktis Oncology in a research report on Wednesday, April 29th. They set an “outperform” rating for the company. Weiss Ratings downgraded shares of Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research report on Tuesday, June 9th. Finally, Raymond James Financial initiated coverage on shares of Aktis Oncology in a research report on Monday. They set a “strong-buy” rating and a $40.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Aktis Oncology Trading Up 6.0%

The business has a 50-day moving average price of $19.29.

Aktis Oncology (NASDAQ:AKTS) last issued its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The business had revenue of $1.87 million for the quarter. As a group, equities analysts anticipate that Aktis Oncology will post -1.62 EPS for the current year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.